After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …

Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …

Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical
data have suggested that use of atorvastatin may be associated with a reduction in cardiac …

Background Patients with cancer may be at high risk of adverse outcomes from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …

PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-
cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug …

Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor …

PURPOSE Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell
lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus …

The medical history of cancer began millennia ago. Historical findings of patients with
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …

Based on the profile of genetic alterations occurring in tumor samples from selected diffuse
large B-cell lymphoma (DLBCL) patients, 2 recent whole-exome sequencing studies …